DocuSign Envelope ID: 93814CCA-7104-4E3F-B3D7-17B1885C5B7D

CONFIDENTIALITY DETERMINATION

Solicitation Number: YH23-0093
Service: Specialty Pharmacy Services for Anti-Hemophilia and Other Blood Disorder Medications RFP
Offeror's Name: InfluCare Rx

In accordance with Arizona state rules and regulations, it is determined that the following records are confidential and exempt from public disclosure as requested by the Offeror listed above:

For a list of specific records to be kept confidential, see the detailed legal analysis contained in the Offeror's Proposal and attached here.

The Offeror has supplied acceptable documentation identifying the portions of the bid along with the specific hard or prejudice which may arise if disclosed.

Signature: DS ML
Title: Chief Procurement Officer
Date: 6/29/2023

DocuSign Envelope ID: 93814CCA-7104-4E3F-B3D7-17B1885C5B7D

InfuCare Rx

P.O. Box 2578
Secaucus, NJ 07096

Tel (877) 828-3940
Fax (877) 828-3941

May 31, 2023

As part of the InfuCare Rx, Inc. ("InfuCare Rx") proposal for AHCCCS Solicitation #YH23-0093, Specialty Pharmacy Services for Anti-Hemophilia and Other Blood Disorder Medication, this request is being submitted to identify certain portions and information contained within the proposal as confidential and proprietary. The information identified below should be withheld from public inspection since it is the confidential and proprietary information of InfuCare Rx (the "Confidential Information"):

- All information contained in, or relating to, the Price Sheet in Part B – B3, Attachment 1.

If the Confidential Information is disclosed to the public, InfuCare Rx may suffer irreparable injury because the Confidential Information is related to the proprietary business process and operations of InfuCare Rx, and disclosure of the Confidential Information may place InfuCare Rx at a competitive disadvantage with respect to its competitors. Additionally, InfuCare Rx is subject to other third-party confidentiality obligations that require InfuCare Rx to maintain the Confidential Information as confidential and proprietary, and public disclosure of the Confidential Information may subject InfuCare Rx to liability with respect to these third-party confidentiality obligations.

Based on the foregoing, the Confidential Information should be withheld from public inspection. If you have any questions, or require additional information, please let me know.

Josh Albert
Associate General Counsel
jalbert@infucarerx.com